--- title: "Pulse Biosciences, Inc (NASDAQ:PLSE) Given Average Rating of \"Moderate Buy\" by Brokerages" type: "News" locale: "en" url: "https://longbridge.com/en/news/296104221.md" description: "Pulse Biosciences (PLSE) holds a 'Moderate Buy' consensus from five analysts, with an average 12-month price target of $45.25. Recent reports include Needham's 'buy' rating at $58 and Canaccord Genuity's raised target to $43. Institutional investors like BNP Paribas and Tower Research increased holdings in Q2. The company recently reported Q2 EPS of ($0.36), missing estimates, with revenue of $0.43 million." datetime: "2026-08-17T12:14:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296104221.md) - [en](https://longbridge.com/en/news/296104221.md) - [zh-HK](https://longbridge.com/zh-HK/news/296104221.md) generator: "portal-rs" --- # Pulse Biosciences, Inc (NASDAQ:PLSE) Given Average Rating of "Moderate Buy" by Brokerages Shares of Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) have received an average recommendation of "Moderate Buy" from the five analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $45.25. Get **Pulse Biosciences** alerts: PLSE has been the subject of several research reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Needham & Company LLC started coverage on shares of Pulse Biosciences in a report on Monday. They issued a "buy" rating and a $58.00 price objective for the company. Canaccord Genuity Group raised their price target on shares of Pulse Biosciences from $32.00 to $43.00 and gave the company a "buy" rating in a research report on Monday, August 10th. Mizuho set a $45.00 target price on Pulse Biosciences in a report on Monday, August 10th. Finally, Oppenheimer restated an "outperform" rating on shares of Pulse Biosciences in a report on Tuesday, July 28th. **Read Our Latest Stock Report on PLSE** ## Institutional Inflows and Outflows A number of large investors have recently made changes to their positions in PLSE. BNP Paribas Financial Markets boosted its position in shares of Pulse Biosciences by 63.6% in the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company's stock worth $26,000 after buying an additional 680 shares during the period. Osterweis Capital Management Inc. bought a new position in shares of Pulse Biosciences in the second quarter valued at approximately $28,000. Tower Research Capital LLC TRC boosted its holdings in Pulse Biosciences by 275.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company's stock worth $44,000 after buying an additional 2,156 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Pulse Biosciences by 13.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company's stock worth $70,000 after buying an additional 619 shares during the period. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Pulse Biosciences in the 2nd quarter valued at about $158,000. Hedge funds and other institutional investors own 76.95% of the company's stock. ## Pulse Biosciences Stock Performance PLSE stock opened at $44.54 on Monday. The firm has a 50-day simple moving average of $30.86 and a two-hundred day simple moving average of $24.74. Pulse Biosciences has a one year low of $12.56 and a one year high of $46.97. The firm has a market cap of $3.08 billion, a price-to-earnings ratio of -37.75 and a beta of 1.61. Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.07). Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%.The company had revenue of $0.43 million during the quarter, compared to analysts' expectations of $0.53 million. As a group, equities analysts predict that Pulse Biosciences will post -1.29 earnings per share for the current fiscal year. ## Pulse Biosciences Company Profile (Get Free Report) Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical. The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions. ## Featured Stories - Five stocks we like better than Pulse Biosciences - JFrog’s AI Opportunity Could Fuel a Big Leap in Share Price - Is SiTime the Best AI Stock You've Never Heard Of? - The Metals Company’s Big Bet Now Comes Down to a License - OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Pulse Biosciences Right Now? Before you consider Pulse Biosciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list. While Pulse Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [PLSE.US](https://longbridge.com/en/quote/PLSE.US.md) - [BNPQY.US](https://longbridge.com/en/quote/BNPQY.US.md) - [MFG.US](https://longbridge.com/en/quote/MFG.US.md) - [8411.JP](https://longbridge.com/en/quote/8411.JP.md) - [OPY.US](https://longbridge.com/en/quote/OPY.US.md) - [MFC.US](https://longbridge.com/en/quote/MFC.US.md) - [FROG.US](https://longbridge.com/en/quote/FROG.US.md) - [SITM.US](https://longbridge.com/en/quote/SITM.US.md) - [TMC.US](https://longbridge.com/en/quote/TMC.US.md) - [OSW.US](https://longbridge.com/en/quote/OSW.US.md) - [TMCWW.US](https://longbridge.com/en/quote/TMCWW.US.md) ## Related News & Research - [Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform](https://longbridge.com/en/news/296024769.md) - [This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday](https://longbridge.com/en/news/296102902.md) - [Is Climb Bio’s (CLYM) Mixed Loss Trends Revealing a Shift in Its Investment Story?](https://longbridge.com/en/news/296222919.md) - [AH Bio Fund IV Discloses Investment at Braveheart Bio with 11.4% Stake](https://longbridge.com/en/news/295977626.md) - [I Love Lund invests SEK 1.54 million in Aligned Bio via share subscription](https://longbridge.com/en/news/296130285.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**